M Tonnelier1,2, A Bouras3, C Joseph3,4, Y El Samad3, B Brunschweiler5, J-L Schmit3,4, C Mabille6, J-P Lanoix3,4. 1. Infectious diseases department, CHU Amiens Nord, 1 place Victor Pauchet, 80000, Amiens, France. mathilde.tonnelier87@gmail.com. 2. Centre hospitalier Compiègne-Noyon - service MIPI, 8 avenue Henri Adnot, 60200, Compiègne, France. mathilde.tonnelier87@gmail.com. 3. Infectious diseases department, CHU Amiens Nord, 1 place Victor Pauchet, 80000, Amiens, France. 4. UR 4294 AGIR, Université Picardie Jules Verne, 1-3 rue des Louvels, 80000, Amiens, France. 5. Orthopedic department, CHU Amiens Sud, 1 rue du Professeur Christian Cabrol, 80054, Amiens, France. 6. Pharmacy department, CHU Amiens Sud, 1 rue du Professeur Christian Cabrol, 80054, Amiens, France.
Abstract
BACKGROUND: Prosthetic joint infections (PJI) are a major cause of morbidity and mortality burden worldwide. While surgical management is well defined, rifampicin (RIF) dose remains controversial. The aim of our study was to determine whether Rifampicin dose impact infection outcomes in PJI due to Staphylococcus spp. METHODS: single-center retrospective study including 411 patients with PJI due to Rifampicin-sensitive Staphylococcus spp. Rifampicine dose was categorized as follow: < 10 mg/kg/day, 10-20 mg/kg/day or > 20 mg/kg/day. The primary endpoint was patient recovery, defined as being free of infection during 12 months after the end of the initial antibiotic course. RESULTS: 321 (78%) received RIF for the full antibiotic course. RIF dose didn't affect patients recovery rate with 67, 76 and 69% in the < 10, 10-20 and > 20 mg/kg/day groups, respectively (p = 0.083). In univariate analysis, recovery rate was significantly associated with gender (p = 0.012) but not to RIF dose, or Staphylococcus phenotype (aureus or coagulase-negative). In multivariate analysis, age (p = 0.01) and treatment duration (p < 0.01) were significantly associated with recovery rate. CONCLUSION: These data suggest that lower doses of RIF are as efficient and safe as the recommended high-dose French regimen in the treatment of PJI.
BACKGROUND:Prosthetic joint infections (PJI) are a major cause of morbidity and mortality burden worldwide. While surgical management is well defined, rifampicin (RIF) dose remains controversial. The aim of our study was to determine whether Rifampicin dose impact infection outcomes in PJI due to Staphylococcus spp. METHODS: single-center retrospective study including 411 patients with PJI due to Rifampicin-sensitive Staphylococcus spp. Rifampicine dose was categorized as follow: < 10 mg/kg/day, 10-20 mg/kg/day or > 20 mg/kg/day. The primary endpoint was patient recovery, defined as being free of infection during 12 months after the end of the initial antibiotic course. RESULTS: 321 (78%) received RIF for the full antibiotic course. RIF dose didn't affect patients recovery rate with 67, 76 and 69% in the < 10, 10-20 and > 20 mg/kg/day groups, respectively (p = 0.083). In univariate analysis, recovery rate was significantly associated with gender (p = 0.012) but not to RIF dose, or Staphylococcus phenotype (aureus or coagulase-negative). In multivariate analysis, age (p = 0.01) and treatment duration (p < 0.01) were significantly associated with recovery rate. CONCLUSION: These data suggest that lower doses of RIF are as efficient and safe as the recommended high-dose French regimen in the treatment of PJI.
Authors: L Grammatico-Guillon; S Baron; S Gettner; A-I Lecuyer; C Gaborit; P Rosset; E Rusch; L Bernard Journal: J Hosp Infect Date: 2012-06-26 Impact factor: 3.926
Authors: Benjamin Zmistowski; Joseph A Karam; Joel B Durinka; David S Casper; Javad Parvizi Journal: J Bone Joint Surg Am Date: 2013-12-18 Impact factor: 5.284
Authors: Javad Parvizi; Ian M Pawasarat; Khalid A Azzam; Ashish Joshi; Erik N Hansen; Kevin J Bozic Journal: J Arthroplasty Date: 2010-05-31 Impact factor: 4.757
Authors: Charlotte Seijger; Wouter Hoefsloot; Inge Bergsma-de Guchteneire; Lindsey Te Brake; Jakko van Ingen; Saskia Kuipers; Reinout van Crevel; Rob Aarnoutse; Martin Boeree; Cecile Magis-Escurra Journal: PLoS One Date: 2019-03-14 Impact factor: 3.240
Authors: Mark Beldman; Claudia Löwik; Alex Soriano; Laila Albiach; Wierd P Zijlstra; Bas A S Knobben; Paul Jutte; Ricardo Sousa; André Carvalho; Karan Goswami; Javad Parvizi; Katherine A Belden; Marjan Wouthuyzen-Bakker Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: Don Bambino Geno Tai; Elie F Berbari; Gina A Suh; Brian D Lahr; Matthew P Abdel; Aaron J Tande Journal: Open Forum Infect Dis Date: 2022-07-25 Impact factor: 4.423
Authors: Henk Scheper; Robert J P van der Wal; Rachid Mahdad; Stefan Keizer; Nathalie M Delfos; Joris C T van der Lugt; Karin Ellen Veldkamp; Peter A Nolte; Masja Leendertse; Luc B S Gelinck; Femke P N Mollema; Emile F Schippers; Hanke G Wattel-Louis; Leo G Visser; Rob G H H Nelissen; Mark G J de Boer Journal: Open Forum Infect Dis Date: 2022-09-13 Impact factor: 4.423